Choice of GPIIb/IIIa antagonist in percutaneous coronary intervention: How should economic criteria be factored in?

Pharmacy World and Science

Volumn 27, Issue 2, 2005, Pages 83-91

  Le Pen, Claude ^a   Lilliu, Hervé ^a  

^a CLP Sante   (France)

Author keywords

Cost effectiveness; Costs; GPIIb IIIa antagonists; Percutaneous coronary interventions; Pharmacoeconomics

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PLACEBO; TIROFIBAN;

ACUTE HEART INFARCTION; CLINICAL TRIAL; CORONARY STENT; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFECT; DRUG EFFICACY; ECONOMIC ASPECT; HOSPITAL COST; HUMAN; META ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; COST-BENEFIT ANALYSIS; DIABETES MELLITUS; DRUG COSTS; HOSPITAL COSTS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MYOCARDIAL INFARCTION; PEPTIDES; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; TIME FACTORS; TREATMENT OUTCOME; TYROSINE;

EID: 19944387631     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-004-2269-1     Document Type: Review

References (35)

1. WB Hillegass AR. Newman DL. Raco 2001 Glycoprotein IIb/IIIa receptor therapy in percutaneous coronary intervention and non-ST-segment elevation acute coronary syndromes Estimating the economic implications. Pharmacoeconomics. 19 1 41 55
2. The EPIC Investigation use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. (1994) 330(14): 956-61
3. The CAPTURE Study Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina. Lancet 1997; 349(9063): 1429-35
4. The EPILOG Investigators platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336(24): 1689-96
5. EJ. Topol DB Mark AM Lincoff E Cohen J Burton N Kleiman N. 1999 Outcomes at lyear and economic implications of platelet glycoprotein-IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial EPISTENT investigators, Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet. 354 9195 2019 24
6. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/ IIIa blockade. Lancet. 1998; 352(9122): 87-92
7. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) study investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338(21): 1498-505
8. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338(21): 1488-97
9. The RESTORE Investigators Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96(5): 1445-53
10. EJ Topol DJ Moliterno HC Herrmann ER Powers CL Grines DJ Cohen 2001 Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization N Engl J Med. 344 25 1888 94
11. The TARGET investigators. Outcomes at 6months for direct comparison of tirfiban and abciximab during percutaneous coronary resvascularization with stent placement: the TARGET follow-up study. Lancet 2002; 360(9330): 355-60
12. The PURSUIT trial investigators, Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339(7): 436-43
13. IMPACT-II, Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention. Lancet 1997; 349(9063): 1422-8
14. JC O'Shea GE Hafley S Greenberg V Hasselblad TJ Lorenz MM Kitt 2001 Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial JAMA. 285 19 2468 73
15. F Locher A Vainchtock C Baptiste P. Pigeon 2000 Observatoire du coût des traitements par GPIIb/IIIa antagonist en cardiologie Et Eval Cardiovasc. 7 33l 58
16. MJ Lage BL Barber PL McCollam M Bala J. Scherer 2001 Impact of abciximab versus tirofiban on hospital length of stay for PCI patients Catheter Cardiovasc Interv. 52 3 298 305
17. PL Collam MJ Lage M. Bala 2001 A comparison of total hospital costs for percutaneous coronary intervention patients receiving abciximab versus tirofiban Catheter Cardiovasc Interv. 54 2 152 7
18. CL. Lucore GJ Mishkel RW. Ligon K. Rocha-Singh 1999 Economic implications of coronary stenting with adjunctive IIb/IIIa receptor antagonists in a community hospital J Invasive Cardiol. 11 Suppl C 14C 20C
19. CR Narins DP Miller RM Califf EJ. Topol 1999 The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization: insights from the EPIC trial Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications J Am ColI Cardiol. 33 3 647 53
20. CP. Cannon 1999 Incorporating platelet glycoprotein IIb/IIIa inhibition in critical pathways: unstable angina/non-ST-segment elevation myocardial infarction Clin Cardiol. 22 Suppl 8 IV30 IV6
21. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000; 356(9247): 2037-44
22. DL Brown CS Fann CJ. Chang 2001 Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention Am J Cardiol. 87 5 537 41
23. EJ Topol AM Lincoff DJ Kereiakes NS Kleiman EA Cohen etal. Ferguson JJ. 2002 Multi-year follow-up of abciximab therapy in three randomized, placebo- controlled trials of percutaneous coronary revascularization Am J Med. 113 1 1 6
24. DL Bhatt SP Marso AM Lincoff KE Wolski SG Ellis EJ. Topol 2000 Abciximab reduces mortality in diabetics following percutaneous coronary intervention J Am Coll Cardiol. 35 4 922 8
25. SJ Brener LA Barr JE Burchenal S Katz BS George AA Jones 1998 Randomized, placebo controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) investigators Circulation. 98 8 734 41
26. G Montalescot P Barragan O Wittenberg P Ecollan S Elhadad etal. Villain P. 2001 Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction N Engl J Med. 344 25 1895 903
27. GW Stone CL Grines DA Cox E Garcia JE Tcheng etal. Griffin JJ. 2002 Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction N Engl J Med. 346 13 957 66
28. Prairie ReoPro versus Integrilin Cost Evaluation (PRICE) Trail. Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention. Am Heart J 2001; 141(3): 402-9
29. DM. Bell 1999 Analysis of number needed to treat and cost of platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary interventions and acute coronary syndromes Pharmacotherapy. 19 9 1086 93
30. CJ Dunn RH Foster Abciximab. 1999 A pharmacoeconomic review of its use in percutaneous coronary revascularisation Pharmacoeconomics. 16 6 711 41
31. C Le Pen J Bonastre P. Pinton 1999 Evaluation Médicoé conomique d'abciximab Ann Cardiol Angéiol. 48 1 1 7
32. DJ Kereiakes RL Obenchain BL Barber A Smith M McDonald etal. Broderick TM. 2000 Abciximab provides cost-effective survival advantage in high-volume interventional practice Am Heart J. 140 4 603 10
33. DB Mark RA Harrington AM Lincoff RM Califf CL Nelson etal. Tsiatis AA. 2000 Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes Circulation. 101 4 366 71
34. RE Brown RA Henderson D Koster J Hutton ML. Simoons 2002 Cost effectiveness of eptifibatide in acute coronary syndromes; an economic analysis of Western European patients enrolled in the PURSUIT trial The Platelet IIa/IIb in unstable angina: receptor suppression using integrilin therapy Eur Heart J. 23 1 50 8
35. PL McCcollam DA Foster JS. Riesmeyer 2003 Cost and effectiveness of glycoprotein IIb/IIIa-receptor inhibitors in patients with acute myocardial infarction undergoing percutaneous coronary intervention Am J Health Syst Pharm. 60 12 1251 6